BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
January 16, 2024 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17
January 11, 2024 16:05 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Issues Letter to Shareholders
December 29, 2023 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity
December 06, 2023 07:00 ET
|
BullFrog AI Holdings, Inc.
The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 ...
BullFrog AI to Present at Benzinga All Access Event on October 20
October 18, 2023 09:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform
October 05, 2023 08:00 ET
|
BullFrog AI Holdings, Inc.
Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a...
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
September 26, 2023 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023
September 25, 2023 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
BullFrog AI Announces Launch of BullFrog Data Networks™, a Data Insights Tool Powered by the bfLEAP™ Platform
September 20, 2023 08:00 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at Maxim Group’s Emerging Growth in AI Virtual Tech Conference Series
September 14, 2023 16:30 ET
|
BullFrog AI Holdings, Inc.
GAITHERSBURG, Md., Sept. 14, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...